Publications

An outline of ImmunoSABR papers, abstracts and reviews.

2020-11-02T23:35:54+01:00

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).

Authors : Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois & Philippe Lambin

2020-11-02T23:33:38+01:00

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.

Authors : Relinde I. Y. Lieverse Damiënne Marcus Alexander M. A. van der Wiel Evert J. Van Limbergen Jan Theys Ala Yaromina Philippe Lambin Ludwig J. Dubois

2020-11-02T23:31:05+01:00

Lymphocyte-Sparing Radiotherapy

Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy

Authors :  PhilippeLambin MD PhD,  Relinde I.Y.Lieverse MD, Franziska Eckert MD , Damiënne Marcus MSc, Cary Oberije PhD, Alexander M.A.van der Wiel MSc, Chandan Guha MD PhD, Ludwig J. Dubois PhD , Joseph O. Deasy PhD

2020-10-04T20:53:10+02:00

Will immunotherapy really change radiotherapy?

Our opinion is to redesign a new framework in a way radiotherapy is delivered to interact most optimally with immunotherapy rather than directly killing as many cells as possible with radiation.

Authors : Philippe Lambin, Relinde Lieverse

STAY INFORMED ?

If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.

NEWSLETTER

SUBSRIBE

CONTACT

The D-Lab / Precision Medicine
P.O. Box 616,
6200 MD Maastricht, The Netherlands

FUNDING

This project has received funding from the European Union’s. Horizon 2020 research and innovation programme under grant agreement No 733008